InnoCare Pharma (HKG: 9969; SHA: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced that the Center for Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA) has approved the registrational Phase III study of the Company’s novel BCL2 inhibitor mesutoclax (ICP‑248) in combination with orelabrutinib for the treatment of patients with marginal zone lymphoma (MZL) who have received at least one prior therapy – marking the fifth registrational clinical trial initiated for mesutoclax.
Regulatory Milestone
| Item | Detail |
|---|---|
| Agency | CDE / NMPA (China) |
| Action | Approval of registrational Phase III clinical trial |
| Product | Mesutoclax (ICP‑248) – novel oral BCL2 inhibitor |
| Combination Partner | Orelabrutinib (BTK inhibitor) |
| Indication | Relapsed/refractory marginal zone lymphoma (MZL) after ≥1 prior therapy |
| Designation | Breakthrough Therapy Designation (BTD) in China for this combination and population |
| Program Position | Fifth registrational trial for mesutoclax |
| Announcement Date | 13 Oct 2026 |
Drug Profile & Mechanism of Action
- Molecule: Mesutoclax (ICP‑248), a novel, oral BCL2 inhibitor independently developed by InnoCare.
- Mechanism: Exerts anti‑tumor activity by selectively inhibiting BCL2 and restoring the normal apoptosis process in cancer cells – re‑engaging programmed cell death in malignant B cells.
- Class Leadership: The first BCL2 inhibitor granted Breakthrough Therapy Designation (BTD) in China, per the Company.
- Combination Rationale: Pairing with the BTK inhibitor orelabrutinib creates a chemotherapy‑free dual‑targeted regimen with complementary mechanisms in B‑cell malignancies.
Clinical Evidence – ASCO 2026 Data in R/R MZL
| Endpoint | Result |
|---|---|
| Overall Response Rate (ORR) | 100% in patients with r/r MZL receiving ≥1 prior therapy |
| Efficacy Profile | Described as excellent |
| Safety Profile | Excellent safety reported |
| Disclosure Venue | 2026 ASCO Annual Meeting |
The 100% ORR presented at ASCO 2026 in this heavily relevant indolent lymphoma population underpins the CDE’s approval of the registrational Phase III program and the prior BTD grant for the combination.
Registrational Pipeline Snapshot – Mesutoclax
| Trial | Setting | Status |
|---|---|---|
| Phase III – mesutoclax + orelabrutinib | 1L CLL/SLL | Enrollment completed |
| Registrational Phase II – mesutoclax monotherapy | BTK inhibitor‑treated MCL | Enrollment completed |
| Head‑to‑head registrational Phase III – mesutoclax + azacitidine vs. venetoclax + azacitidine | Treatment‑naïve AML | Initiated in China |
| Registrational Phase III – mesutoclax + orelabrutinib | R/R MCL | Ongoing in China |
| Registrational Phase III – mesutoclax + orelabrutinib | R/R MZL (this approval) | Approved to initiate |
| Global development – AML and MDS | Multi‑region | Accelerating in China, U.S. and Australia |
Five registrational clinical trials are now underway across B‑cell lymphomas and myeloid malignancies, spanning indolent and aggressive indications in both hematology pillars.
Disease Background – Marginal Zone Lymphoma
- Classification: MZL is an indolent B‑cell non‑Hodgkin’s lymphoma (NHL).
- China Epidemiology: The second most prevalent lymphoma in China, accounting for 8.3% of all lymphomas; it mainly affects middle‑aged and elderly people.
- Global Trend: The annual incidence of MZL has increased globally, expanding the addressable patient population.
Market Impact & Outlook
- China Hemato‑Oncology Leadership: As the first BCL2 inhibitor with a Chinese BTD, mesutoclax is positioned to become a globally competitive innovative therapy, consolidating InnoCare’s leading position in hemato‑oncology, per Dr. Jasmine Cui, Co‑founder, Chairwoman and CEO.
- Venetoclax Head‑to‑Head Challenge: The head‑to‑head registrational Phase III versus venetoclax + azacitidine in treatment‑naïve AML sets up a potential direct efficacy showdown with the current BCL2 standard of care – a high‑stakes differentiator if positive.
- Chemo‑Free Combination Strategy: The mesutoclax + orelabrutinib doublet extends across CLL/SLL, MCL and now MZL, building a franchise‑style indication matrix analogous to proven BCL2/BTK combinations.
- Global Footprint Expansion: Accelerating AML/MDS development across China, the U.S. and Australia signals ambitions beyond the domestic market, with partnership and registration potential in major geographies.
- Indolent Lymphoma Opportunity: With MZL incidence rising and treatment options limited after prior therapy, a 100% ORR combination could redefine second‑line standards in this underserved NHL subtype.
Forward‑Looking Statements
This brief contains forward‑looking statements regarding clinical trial progression, regulatory approvals and commercial potential of mesutoclax and its combinations. Actual results may differ materially due to risks including Phase III trial outcomes, head‑to‑head comparative results, regulatory review timelines in China, the U.S. and Australia, and competitive dynamics among BCL2 inhibitors and B‑cell malignancy therapies.-Fineline Info & Tech
